Editas Medicine (EDIT) Receivables - Net (2015 - 2025)

Editas Medicine (EDIT) has reported Receivables - Net for 11 consecutive years, with $15.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables - Net fell 6.7% year-over-year to $15.2 million; the TTM figure through Dec 2025 stood at $15.2 million (down 6.7% YoY), while the FY2025 annual figure was $15.2 million, down 6.7% from the prior year.
• Receivables - Net improved to $15.2 million in Q4 2025 per EDIT's latest filing, from $8.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $16.3 million in Q4 2024 and bottomed at $120000.0 in Q3 2022.
• Historically, Receivables - Net has averaged $3.3 million across 5 years, with a median of $630000.0 in 2021.
• Annual changes were most pronounced in 2021 — Receivables - Net sank 95.59% — and 2025, when it surged 6352.38%.
• Editas Medicine's Receivables - Net stood at $267000.0 in 2021, then jumped by 1826.97% to $5.1 million in 2022, then surged by 98.0% to $10.2 million in 2023, then soared by 59.67% to $16.3 million in 2024, then fell by 6.7% to $15.2 million in 2025.
• Business Quant data shows EDIT's Receivables - Net at $15.2 million in Q4 2025, $8.1 million in Q3 2025, and $588000.0 in Q2 2025.